2024 Outlook: Tenet Healthcare Forecasts 2024 Adjusted EPS Of $10.41-$11.12 Compared To Prior Guidance Of $8.37-$9.41 And Consensus Of $8.98, Revenues Of $20.6B-$21B Compared To Prior Guidance Of $20B-$20.4B And Consensus Of $20.493B
2024 Outlook: Tenet Healthcare Forecasts 2024 Adjusted EPS Of $10.41-$11.12 Compared To Prior Guidance Of $8.37-$9.41 And Consensus Of $8.98, Revenues Of $20.6B-$21B Compared To Prior Guidance Of $20B-$20.4B And Consensus Of $20.493B
2024 Outlook1
2024展望1
Tenet's Outlook for full year 2024 (consolidated and by segment) and third quarter 2024 follows. This outlook reflects the completion of the sale of three Coastal South Carolina hospitals on January 31, 2024 and the completion of the sale of six California hospitals on March 31, 2024.
2024年全年展望（按業務板塊和綜合業務）和2024年第三季度展望如下。此展望反映了於2024年1月31日完成三家南卡羅來納州沿海醫院的出售，以及於2024年3月31日完成六家加利福尼亞州醫院的出售。
| CONSOLIDATED ($ in millions, except per share amounts) | FY 2024 Outlook | Third Quarter |
| Net operating revenues | $20,600 to $21,000 | $5,000 to $5,100 |
| Net income available to Tenet common stockholders | $2,825 to $2,930 | $195 to $240 |
| Adjusted EBITDA | $3,825 to $3,975 | $900 to $950 |
| Adjusted EBITDA margin | 18.6% to 18.9% | 18.0% to 18.6% |
| Diluted income per common share | $28.83 to $29.90 | $2.01 to $2.47 |
| Adjusted net income | $1,020 to $1,090 | $210 to $250 |
| Adjusted diluted earnings per share | $10.41 to $11.12 | $2.16 to $2.58 |
| Equity in earnings of unconsolidated affiliates | $260 to $270 | $60 to $70 |
| Depreciation and amortization | $830 to $860 | $210 to $220 |
| Interest expense | $815 to $825 | $195 to $205 |
| Income tax expense5 | $1,040 to $1,075 | $90 to $105 |
| Net income available to NCI | $820 to $870 | $195 to $205 |
| Weighted average diluted common shares | ~98 million | ~97 million |
| NCI cash distributions | $725 to $775 | |
| Net cash provided by operating activities6 | $1,900 to $2,250 | |
| Adjusted net cash provided by operating activities6 | $2,025 to $2,325 | |
| Capital expenditures | $800 to $900 | |
| Free cash flow6 | $1,100 to $1,350 | |
| Adjusted free cash flow6 | $1,225 to $1,425 |
| 綜合業務（金額爲百萬美元，除每股數據外） | FY 2024 展望 | 第三季度 |
| 營業淨收入 | 20600至21000 | 5000至5100 |
| 淨利潤（可供Tenet普通股股東支配的淨額） | 2825至2930 | 195至240 |
| 調整後的EBITDA | 3825至3975 | 900至950 |
| 調整後的EBITDA率 | 18.6%至18.9% | 18.0%至18.6% |
| 攤薄每股收益 | $28.83至$29.90 | $2.01至$2.47 |
| 調整後淨利潤 | $1020至$1090 | $210至$250 |
| 調整後的攤薄每股收益 | $10.41至$11.12 | $2.16至$2.58 |
| 合營企業及聯營企業的權益持有份額收益 | $260至$270 | $60至$70 |
| 折舊和攤銷 | $830至$860 | $210至$220 |
| 利息費用 | $815至$825 | $195至$205 |
| 所得稅費用5 | $1,040至$1,075 | $90至$105 |
| 淨利潤歸屬於新華保險的股東 | $820至$870 | $195至$205 |
| 加權平均攤薄普通股股份 | 約9800萬 | 約9700萬 |
| 新華保險的現金分配 | $725至$775 | |
| 經營活動產生的淨現金流量6 | $1,900至$2,250 | |
| 調整後經營活動產生的淨現金流量6 | $2,025至$2,325 | |
| 資本支出 | 800至900美元 | |
| 自由現金流6 | $1,100至$1,350 | |
| 調整後的自由現金流6 | 1,225美元至1,425美元 |
| Ambulatory Segment ($ in millions) | FY 2024 Outlook |
| Net operating revenues | $4,325 to $4,475 |
| Adjusted EBITDA | $1,750 to $1,810 |
| NCI | $685 to $715 |
| Adjusted EBITDA less NCI | $1,065 to $1,095 |
| Changes versus prior year7: | |
| Surgical cases volumes | Up 1.0% to 2.0% |
| Net revenues per surgical case | Up 4.5% to 5.5% |
| 門診部門（以百萬美元計） | FY 2024 展望 |
| 營業淨收入 | 4,325美元至4,475美元 |
| 調整後的EBITDA | 1,750美元至1,810美元 |
| 新華保險 | 685美元至715美元 |
| 調整後的EBITDA減去新華保險 | 1,065美元至1,095美元 |
| 相對於去年的變化7: | |
| 手術病例數量 | 上升1.0％至2.0％ |
| 每個手術病例的淨收入 | 提高4.5％至5.5％ |
| Hospital Segment ($ in millions) | FY 2024 Outlook |
| Net operating revenues | $16,275 to $16,525 |
| Adjusted EBITDA | $2,075 to $2,165 |
| NCI | $135 to $155 |
| Changes versus prior year7: | |
| Inpatient admissions | Up 3.0% to 4.0% |
| Adjusted admissions | Up 1.0% to 3.0% |
| 醫院部門（以百萬美元計） | FY 2024 展望 |
| 營業淨收入 | 16,275美元至16,525美元 |
| 調整後的EBITDA | 2,075美元至2,165美元 |
| 新華保險 | 135美元至155美元 |
| 相對於去年的變化7: | |
| 住院患者人次 | 上升3.0％至4.0％ |
| 調整後的入院人次 | 上漲1.0％至3.0％ |
